Use of Topical Tranexamic Acid or Aminocaproic Acid to Prevent Bleeding After Major Surgical Procedures
- 1 January 2012
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 46 (1), 97-107
- https://doi.org/10.1345/aph.1q383
Abstract
OBJECTIVE: To evaluate the literature describing topical use of tranexamic acid or aminocaproic acid for prevention of postoperative bleeding after major surgical procedures. DATA SOURCES: Literature was retrieved through MEDLINE (1946-September 2011) and International Pharmaceutical Abstracts(1970-September 2011) using the terms tranexamic acid, aminocaproic acid, antifibrinolytic, topical, and surgical. In addition, reference citations from publications identified were reviewed. STUDY SELECTION AND DATA EXTRACTION: All identified articles in English were evaluated. Clinical trials, case reports, and meta-analyses describing topical use of tranexamic acid or aminocaproic acid to prevent postoperative bleeding were included. DATA SYNTHESIS: A total of 16 publications in the setting of major surgical procedures were included; the majority of data were for tranexamic acid. For cardiac surgery, 4 trials used solutions containing tranexamic acid (1-2.5 g in 100-250 mL of 0.9% NaCl), and 1 trial assessed a solution containing aminocaproic acid (24 g in 250 mL of 0.9% NaCl). These solutions were poured into the chest cavity before sternotomy closure. For orthopedic procedures, all of the data were for topical irrigation solutions containing tranexamic acid (500 mg-3 g in 50-100 mL of 0.9% NaCl) or for intraarticular injections of tranexamic acid (250 mg to 2 g in 20-50 mL of 0.9% sodium chloride, with or without carbazochrome sodium sulfate). Overall, use of topical tranexamic acid or aminocaproic acid reduced postoperative blood loss; however, few studies reported a significant reduction in the number of packed red blood cell transfusions or units given, intensive care unit stay, or length of hospitalization. CONCLUSIONS: Topical application of tranexamic acid and aminocaproic acid to decrease postsurgical bleeding after major surgical procedures is a promising strategy. Further data are needed regarding the safety of this hemostatic approach.Keywords
This publication has 63 references indexed in Scilit:
- 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice GuidelinesThe Annals of Thoracic Surgery, 2011
- Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin eraCurrent Opinion in Anaesthesiology, 2011
- Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studiesEuropean Journal of Cardio-Thoracic Surgery, 2010
- Antifibrinolytics in Major Orthopaedic SurgeryJournal of the American Academy of Orthopaedic Surgeons, 2010
- A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac SurgeryThe New England Journal of Medicine, 2008
- Pharmacologic methods to reduce perioperative bleedingTransfusion, 2008
- Absorbable hemostatic agentsAmerican Journal of Health-System Pharmacy, 2006
- Practice Guidelines for Perioperative Blood Transfusion and Adjuvant TherapiesAnesthesiology, 2006
- Effect of blood transfusion on long-term survival after cardiac operationThe Annals of Thoracic Surgery, 2002
- Pharmacological Strategies to Decrease Transfusion Requirements in Patients Undergoing SurgeryDrugs, 2002